LAS VEGAS, April 10, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies for the treatment of early to moderate Parkinson's disease ("PD").
read more here
Delivered by @can_nab_is
No comments:
Post a Comment